News coverage about Minerva Neurosciences (NASDAQ:NERV) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Minerva Neurosciences earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1715310632978 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research firms have issued reports on NERV. Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. ValuEngine downgraded Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $13.94.
Minerva Neurosciences (NERV) traded up $0.20 during trading hours on Friday, hitting $6.25. The company had a trading volume of 383,022 shares, compared to its average volume of 201,688. The firm has a market capitalization of $234.14, a P/E ratio of -5.58 and a beta of 1.53. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $11.90.
In related news, CFO Geoff Race sold 5,829 shares of Minerva Neurosciences stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the sale, the chief financial officer now owns 197,698 shares of the company’s stock, valued at $1,144,671.42. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 12,590 shares of company stock worth $73,073. 21.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2018/01/13/minerva-neurosciences-nerv-receiving-somewhat-positive-news-coverage-analysis-finds.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.